Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Prenetics Global Limited Class A Ordinary Share (PRE)

Prenetics Global Limited Class A Ordinary Share (PRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,993
  • Shares Outstanding, K 9,137
  • Annual Sales, $ 21,740 K
  • Annual Income, $ -62,720 K
  • EBIT $ -46 M
  • EBITDA $ -38 M
  • 60-Month Beta -0.18
  • Price/Sales 2.45
  • Price/Cash Flow N/A
  • Price/Book 0.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +192,215.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.21 +34.09%
on 12/03/24
5.94 -4.88%
on 12/26/24
+1.35 (+31.40%)
since 12/02/24
3-Month
3.87 +45.99%
on 10/09/24
5.94 -4.88%
on 12/26/24
+1.51 (+36.47%)
since 10/02/24
52-Week
2.85 +98.25%
on 04/19/24
7.84 -27.92%
on 04/24/24
+0.03 (+0.53%)
since 01/02/24

Most Recent Stories

More News
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024

RALEIGH, NC / ACCESSWIRE / December 6, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Winter Conference" is taking place on December 10-11, 2024.

IPWR : 7.60 (+0.66%)
HPAI : 6.10 (+9.91%)
PRE : 5.65 (-2.59%)
ANIX : 2.34 (+0.86%)
INUV : 0.7250 (+12.16%)
BNZI : 1.4950 (-2.29%)
DHX : 1.8506 (+4.55%)
AZ : 6.75 (+1.96%)
NXGL : 4.15 (-6.95%)
NTWK : 2.59 (-1.15%)
CDZI : 5.18 (-0.38%)
IM8 Partners with University of Oxford for Groundbreaking Space Experiment on Aging Aboard the ISS

IM8's space experiment on ISS studies accelerated aging to improve healthspan on Earth and astronaut health.Quiver AI SummaryIM8, a premium supplements brand, has initiated a significant month-long experiment...

PRE : 5.65 (-2.59%)
Prenetics Global Limited Reports 59.4% Revenue Growth and Launches Premium Supplement Brand IM8Health.com

Prenetics reported 59.4% revenue growth, launched IM8Health.com, and received $30 million from Tencent for cancer detection venture.Quiver AI SummaryPrenetics Global Limited reported a significant revenue...

PRE : 5.65 (-2.59%)
Prenetics Partners with David Beckham to Launch IM8, a New Health and Wellness Brand Targeting the Global Consumer Health Market

Prenetics and David Beckham launch IM8, a new health brand offering premium wellness products to 31 countries.Quiver AI SummaryPrenetics, a leading health sciences company, has launched IM8, a new health...

PRE : 5.65 (-2.59%)
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

PRE : 5.65 (-2.59%)
Why Prenetics Global Stock Is Skyrocketing Today

The company announced a key FDA clearance.

PRE : 5.65 (-2.59%)
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics

HONG KONG, Dec 16, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT,...

PRE : 5.65 (-2.59%)
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON AND HONG KONG, Nov 30, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its...

PRE : 5.65 (-2.59%)
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON AND HONG KONG, Nov 10, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited...

HSBC : 48.89 (-1.15%)
PRE : 5.65 (-2.59%)
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

LONDON AND HONG KONG, Sep 9, 2022 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited...

PRE : 5.65 (-2.59%)

Business Summary

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof....

See More

Key Turning Points

3rd Resistance Point 6.03
2nd Resistance Point 5.91
1st Resistance Point 5.86
Last Price 5.65
1st Support Level 5.69
2nd Support Level 5.57
3rd Support Level 5.52

See More

52-Week High 7.84
Fibonacci 61.8% 5.93
Last Price 5.65
Fibonacci 50% 5.34
Fibonacci 38.2% 4.76
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar